Cargando…

New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: a case report

BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs) including thyroid dysfunction. There are only a few reports on Graves’ disease induced by ICIs. We report a case of new-onset Graves’ disease after the initiation of nivolumab therapy in a patient receiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamada, Hiroshi, Okajima, Fumitaka, Onda, Takeshi, Fujimori, Shunji, Emoto, Naoya, Sugihara, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449083/ https://www.ncbi.nlm.nih.gov/pubmed/32847555 http://dx.doi.org/10.1186/s12902-020-00613-5

Ejemplares similares

Risk Preferences, Rationality of Choices, and Willingness to Pay for Preventive Medicine in Patients with Graves’ Thyrotoxicosis
por: Emoto, Naoya, et al.
Publicado: (2021)

Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin
por: Okajima, Fumitaka, et al.
Publicado: (2017)

Behavioral economics survey of patients with type 1 and type 2 diabetes
por: Emoto, Naoya, et al.
Publicado: (2015)

A socioeconomic and behavioral survey of patients with difficult-to-control type 2 diabetes mellitus reveals an association between diabetic retinopathy and educational attainment
por: Emoto, Naoya, et al.
Publicado: (2016)

Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal‐bolus insulin therapy: An open‐label, single‐center, parallel, randomized control study
por: Okajima, Fumitaka, et al.
Publicado: (2016)

Basal–Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
por: Okajima, Fumitaka, et al.
Publicado: (2018)

Painless destructive thyroiditis in a patient with resistance to thyroid hormone: a case report
por: Nagamine, Tomoko, et al.
Publicado: (2019)

Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer
por: Yamasaki, Masahiro, et al.
Publicado: (2017)

Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy
por: Lee, Senhong, et al.
Publicado: (2018)

An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer
por: Naganuma, Ken, et al.
Publicado: (2022)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Gastric acid level of humans must decrease in the future
por: Fujimori, Shunji
Publicado: (2020)

SAT-463 Thyrotoxicosis from Nivolumab in a Patient with Preexisting Graves’ Disease
por: Polavarapu, Preethi, et al.
Publicado: (2020)

New-onset insulin-dependent diabetes due to nivolumab
por: Zaied, Ali A, et al.
Publicado: (2018)

Late Onset of Cardiac Metastasis of a Melanoma following Nivolumab Immunotherapy
por: Nakamura, Kenta, et al.
Publicado: (2022)

Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab
por: Olsen, Eric, et al.
Publicado: (2023)

Frequency of Achilles Tendon Xanthoma in Patients with Acute Coronary Syndrome
por: Harada, Taro, et al.
Publicado: (2017)

IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA
por: Oba, Utako, et al.
Publicado: (2020)

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient
por: Yatsuda, Yukino, et al.
Publicado: (2020)

A Grave Initial Presentation of Graves’ Disease in a Patient With Moyamoya
por: Clutter, Courtney, et al.
Publicado: (2021)

Comparison of three α‐glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes
por: Sugihara, Hitoshi, et al.
Publicado: (2013)

Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer
por: Iikura, Yusuke, et al.
Publicado: (2022)

MON-LB112 Socioeconomic Status, Literacy, and Sex Differences in the Progression of Retinopathy in Patients With Type 2 Diabetes in Tokyo, Japan
por: Emoto, Naoya, et al.
Publicado: (2020)

The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma
por: Yazaki, Tomotaka, et al.
Publicado: (2021)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

Radiofrequency ablation therapy – the grave for GAVE (gastric antral vascular ectasia)?
por: Peter, Shajan, et al.
Publicado: (2015)

Nivolumab-related Sclerosing Cholangitis in Gastric Cancer
por: Motoo, Yoshiharu
Publicado: (2019)

New‐onset type 1 diabetes and Graves' disease after antiretroviral therapy in a patient with human immunodeficiency virus infection
por: Taguchi, Maho, et al.
Publicado: (2023)

Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer
por: Hagi, Takaomi, et al.
Publicado: (2020)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma
por: Baroud, Sarah, et al.
Publicado: (2021)

First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer
por: Oda, Hiroyasu, et al.
Publicado: (2019)

Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer
por: Ohmura, Hirofumi, et al.
Publicado: (2023)

Successful treatment of gastric cancer after complete response of lung cancer by nivolumab: a case report
por: Endo, Shunji, et al.
Publicado: (2020)

Significance of Lipopolysaccharides in Gastric Cancer and Their Potential as a Biomarker for Nivolumab Sensitivity
por: Nakazawa, Nobuhiro, et al.
Publicado: (2023)

Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy
por: Gambichler, Thilo, et al.
Publicado: (2018)

SAT-456 Reduced Cholesterol Absorption and Synthesis Markers in Patients with Hyperthyroidism Due to Graves’ Disease
por: Nagamine, Tomoko, et al.
Publicado: (2020)

Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
por: Toyota, Satoshi, et al.
Publicado: (2020)

Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report
por: Shibata, Chikako, et al.
Publicado: (2019)

Superior Mesenteric Artery Syndrome Accompanied by Acute-onset Type 1 Diabetes Complicated with Graves' Disease
por: Sue-Nagumo, Mai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_07a675cop3e07rc2967ke38qs6